title: Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
abstract: Pheochromocytomas, paragangliomas, and medullary thyroid carcinomas (MTCs) originate in cells that share a common neuroectodermal origin. Like other neuroendocrine neoplasms, they are characterized by a propensity to secrete amines (epinephrine and norepinephrine) and peptide hormones (calcitonin). Improved understanding of underlying molecular pathways, such as mutations of the RET (rearranged during transfection) proto-oncogene, has led to new rational targeted therapies. Adrenocortical carcinomas (ACCs) originate in the steroid hormone-producing adrenal cortex. While tumors of the adrenal cortex are not, strictly speaking, part the "diffuse neuroendocrine system," they are often included in neuroendocrine tumor guidelines due to their orphan status. In this update on management of unusual neuroendocrine tumors, we review the biology and treatment of these rare neoplasms.
authors: Gastrointestinal and Neuroendocrine Tumor Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. jonathan.strosberg@moffitt.org
authors: Jonathan R
authors: JR
authors: Strosberg
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000310:Adrenal Gland Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D018268:Adrenocortical Carcinoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D018278:Carcinoma, Neuroendocrine; D020022:Genetic Predisposition to Disease; D006801:Humans; D010235:Paraganglioma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D010673:Pheochromocytoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000090063:Proto-Oncogene Mas; D013964:Thyroid Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome